1. Introduction
===============

Feline infectious peritonitis (FIP) is a fatal disease of cats caused by feline coronavirus (FCoV) infection. There are two serotypes ([@BIB8]; [@BIB17]), type I being more prevalent in field conditions ([@BIB16]), accounting for at least 70% of FIP cases. However, to date, most vaccine attempts have been based on serotype II. Development of vaccines has been largely unsuccessful, with traditional approaches sometimes serving to exacerbate disease through antibody dependentenhancement (ADE). The identification of FCoV epitopes responsible for neutralisation and enhancement is still under investigation. Attempts at vaccination have included the use of avirulent FCoV ([@BIB21]), recombinant vaccina virus expressing the S protein ([@BIB33]), non-feline coronaviruses ([@BIB5], [@BIB4]; [@BIB30]) and plasmids expressing M or N proteins alone, or with enhancement through vaccinia viruses or feline cytokines ([@BIB10]). A commercial vaccine ([@BIB7]) was launched in 1991 (Primucell-FIP™, Pfizer Animal Health), however, its safety remains controversial and it is not licensed for kittens less than 16 weeks old ([@BIB19]; [@BIB29]).

Generation of mucosal immunity may be critical to prevent FCoV infection and FIP. A strong cellular immune response, through the induction of type I immunity, appears to be the key to virus control (reviewed by [@BIB20]). Minimisation of the development of humoral antibodies may be valuable in avoiding ADE of infection and immune complex deposition. Expression of serotype 1 FCoV epitopes that induce a protective response using a virus vector from a different family may provide a solution and would reduce the risk of virus recombination. Retroviral vectors may act as suitable candidates as they are persistent, integrating a proviral copy of their genome into the host DNA, from which protein expression occurs whenever transcription of that region is initiated. Spumaviruses offer several potential advantages over the more traditionally explored retroviral vectors. They have a large genome size; a wide cellular host range; are relatively apathogenic and require the presence of the viral transactivator (Tas) for high level transcription from the viral long terminal repeat (LTR). The latter factor enables the development of replication-incompetence, as deletion of the transactivator prevents transcription of the structural genes. Supplying this protein *in trans*, via a helper cell line, allows the production of an infectious viral particle able to infect a susceptible cell and integrate. However, such an infection would be abortive, unable to produce infectious virions because of the lack of Tas in the target cell.

This paper describes the initial phases in the development of feline foamy virus vectors for investigation as candidate vaccines for FIP, using a Tas-dependent, replication incompetent system.

2. Materials and methods
========================

2.1. Construction of the helper cell line
-----------------------------------------

FFV strain F-17 has been sequenced ([@BIB11]) and the genomic organisation determined ([Fig. 1](#FIG1){ref-type="fig"} ). *tas* was amplified from the F-17 genome by polymerase chain reaction (PCR), gel purified, restriction digested and ligated into a pHook-3 plasmid (Invitrogen, Paisley, UK) by standard techniques. The positive control plasmid, pHook-3/His/LacZ (Invitrogen), contained the *lac Z* gene under the CMV promoter.Figure 1Diagrammatic representation of the feline foamy virus (FFV) genome. FFV has the typical retroviral organisation, consisting of a 5′ and 3′ LTR and the main structural genes *gag*, *pol* and *env*. It also contains two accessory open reading frames (*bel1/tas* and *bel2*), as compared to prototypic and simian foamy viruses, which have three. *tas* encodes for the viral transactivator Tas, which drives temporal expression from the internal promoter (IP) at the 3′ end of *env* and the 5′ LTR U3 promoter. Bet is produced as a splice protein from the 5′ region of *tas* and *bel2*, as indicated.

Plasmids were grown in *Escherichia coli* DH5a and purified as endotoxin-free (Endofree Plasmid Maxi Kit, Qiagen, Crawley, UK). Confirmation of the integrity of the plasmids was achieved through PCR (pHook-3/tas) and restriction digests (pHook-3/lacZ), with the products visualised by agarose gel electrophoresis. The functionality of these plasmids was investigated through transfection assays and *β*-galactosidase staining. A cationic lipid-based transfection system (Lipofectamine, Invitrogen) was used to carry plasmid DNA into FKCU/LTR/zeo/*β*-gal reporter cells (a kind gift from Prof. A. Rethwilm, University of Wurzburg, Germany). These cells contain the *lacZ* gene under the control of the FFV LTR. Production of functional Tas by transfected cells would result in transcription of the *lacZ* gene. The *β*-galactosidase produced catalyses the hydrolysis of *β*-galactosides. The substrate 'X-gal' (5-bromo-4-chloro-3-indolyl-*β*-[d]{.smallcaps}-galactopyranoside) produces a blue coloured product when cleaved by *β*-galactosidase, which can be visualised by light microscopy.

2.2. Transfection of CRFK cells and cell cloning
------------------------------------------------

CRFK cells were transfected with pHook3/tas plasmids in an optimised assay, the positive cells being selected through antibiotic resistance and serially diluted to obtain single cell clones. In parallel, CRFK cells were transfected with pHook3/*β*gal, dilution cloned, grown for 3 weeks and then stained to assess the effectiveness of the procedure.

2.3. Analysis of helper cell clones
-----------------------------------

Once single cell clones had been generated, they were analysed by immunofluorescence, PCR and through transfection assays. A second reporter plasmid was used for this purpose (pLTR1/(FFV)/*β*-gal/zeo, a kind gift from Prof. A. Rethwilm), which contained the *lacZ* gene under the control of the FFV U3-LTR promoter. If the helper cell line clone were to express functional Tas, the LTR promoter would be activated, which would allow expression from the *lacZ* gene. *β*-galactosidase production could then be assessed by the standard colourimetric assay. CRFK cells were transfected in parallel to act as a negative control.

Vector constructs, containing the eGFP gene in place of the viral transactivator, were used to investigate packaging ability and the generation of virions able to infect feline cells. Vectors were transfected into the helper cells using Lipofectamine (Invitrogen). Cells were passaged and monitored for the eGFP fluorescence.

3. Results
==========

Optimisation of the transfection method resulted in transfection efficiencies averaging 30% ([Fig. 2](#FIG2){ref-type="fig"} ). Helper cell line clones (CRFK/tas) were developed over a 5-month period, with cell clones being grown to confluency, expanded, tested and frozen as stocks. Thirty-two CRFK/tas single cell clones were identified. Seven of these clones were found to express functional Tas, with efficiencies ranging from 25--60% ([Fig. 3](#FIG3){ref-type="fig"} ).Figure 2FKCU/LTR reporter cells, transfected with the pHook-3/tas plasmid and stained by the *β*-galassay. Transfection efficiency approximated as 25--30%, based on the development of blue-coloured cells. (Magnification ×200).Figure 3Microscopic appearance of CRFK/tas/pLTR1/(FFV) cell clones following *β*-gal staining. (a) Cell line with 50% blue cells, (b) Cell line with 30% blue cells. (Magnification ×100 and ×200).

PCR of the functional helper cell line clones for the presence of the *tas* gene insert revealed all to be positive for a 600 b.p. band, consistent with the expected size of the *tas* gene. The homogeneity of expression of the helper cell lines has subsequently been assessed and further studies into Tas are underway.

Helper cell lines were transfected with the replication-incompetent, *tas*-deleted vectors, containing the eGFP gene cassette. Fluorescence was detected in 10--20% of cells using an inverted fluorescence microscope. The ability of these vectors to replicate in the helper cell lines and transfer to independent cell cultures is being investigated.

4. Discussion
=============

Viral vectors have been developed for human gene therapy applications in recent years, though many current vehicles remain either inefficient or potentially unsafe. The unique biology of the foamy viruses lends themselves to development as such vectors, particularly their reported lack of pathogenicity. In humans, zoonotic infection with simian FV (SFV) has been reported and it is now thought that human FV (renamed prototypic (P)FV) was originally a zoonotic infection with SFVcpz([@BIB15]). SFV infection in man has been reported as apathogenic, in studies involving up to a 23-year monitoring period, and man appears to be a dead-end host ([@BIB13]). Despite links to a number of diseases, including de Quervain thyroiditis ([@BIB34]), Graves disease ([@BIB18]) and Ménière disease ([@BIB23]), no studies have subsequently confirmed these associations (reviewed by [@BIB12]). There have been reports of association of FFV with feline polyarthropathy ([@BIB22]) and a cofactor effect with FIV ([@BIB37]; [@BIB38]), but these reports have not been confirmed by other workers in the field and there is no convincing evidence of any direct pathology associated with infection. Studies have shown FFV to be relatively ubiquitous in the domestic and feral cat populations, with seroprevalences ranging from 5--100%, with over 50% for most populations ([@BIB3]; [@BIB9];[@BIB35], [@BIB36], [@BIB37]). It has been concluded from phylogenetic analyses that simian foamy viruses have a long history of coexistence and coevolution with their hosts ([@BIB15]; [@BIB28]) and this may apply to FFV and cats. Experimental infections in cats have provided no evidence of pathology or clinical signs of disease([@BIB2]; [@BIB26]). Thus, although the issue of pathogenicity cannot be completely ruled out, most evidence suggests the virus is non-pathogenic. We are currently investigating the possibility of pathogenicity associated with FFV experimental infection of cats.

The paper describes the initial phases of the production of a *tas*-deleted, replication incompetent vector system, reliant on a Tas packaging cell line. Work to date has produced a functional, homogenous CRFK/tas helper cell line and current work is assessing the function of eGFP containing vectors. Preliminary results have indicated a failure of passage of the vectors, despite adequate transfection efficiencies. This could be due to a packaging problem, the 470 bp deleted *tas* fragment having been replaced with a 1.4 kb eGFP cassette. Alternatively, the disruption of Bet (a splice protein produced at high levels during viral replication, see [Fig. 1](#FIG1){ref-type="fig"}), due to the *tas* deletion, may be responsible. Bet has been shown to be indispensable for in vitro FFV replication ([@BIB1]). Current studies are looking at supplying Bet *in trans* and reducing the foreign gene insert size to investigate these issues.

There have been various phases in FV vector development by other workers to date. Initial work looked at *tas*-deleted systems, where the accessory genes±portions of *env* were replaced with a reporter gene or gene of interest, then *tas* supplied*in trans* ([@BIB6]; [@BIB24]). Replication competent vectors were produced by substituting the *orf2* gene with the gene of interest, retaining *tas* ([@BIB25]). The inserted gene was expressed as a fusion protein to Bet, with either a coding sequence from the self-cleaving FMD virus 2A protease or an internal ribosomal entry site to allow recombinant protein production. These foreign genes were placed under the control of a heterologous promoter to enable high level expression.

More recently, vectors have been developed by replacing the U3 region of the 5′ LTR with the CMV promoter, allowing Tas-independent vector production at high levels ([@BIB31]). On reverse transcription, the 5′ U3 is restored, producing double stranded vector DNA that integrates, but as the virus is *tas*-deleted, there is no viral replication. Additional deletion of Tas responsive elements and the TATA box from the 3′ U3 region eliminates the risk of activation of the FV U3 promoter by cellular components ([@BIB14]). Finally, minimal construct vectors have been produced using PFV, which depend on a co-transfection system to supply *gag*, *pol* and *env in trans* ([@BIB32]). FFV appears to be more difficult to manipulate than PFV in vector development, there being striking biological differences between the two viruses, particularly in the absolute requirement of Bet for FFV replication ([@BIB1]). However, FFV vectors are being developed, and have been applied recently in an experimental study looking at vaccination against feline calicivirus ([@BIB27]).

Application of these vectors to tackling the problems of vaccine development for FIP is a new approach, aimed at potentiating the cell mediated immune response and provide persistent protection in the face of high environmental FCoV load. Further development of the vector system is required. Identification and cloning of coronavirus epitopes which are neutralising, but not enhancing, using FCoV serotype I strains, will enable characterisation of FCoV antigens which are most likely to give an effective vaccine response. Construction and assessment of FFV/FCoV antigen vectors will allow the determination of the value of these constructs as potential vaccines.

Thus, FFV has shown its potential for development as a viral vector and vaccination against FIP using such a vector is an exciting application of gene therapy technology in the cat. Since this is a new area of biotechnology in feline medicine, further investigation into issues of biosafety and applications need to be investigated before this technology becomes available to the clinician.
